935288-20-3

Basic information

• Product Name: 1-broMo-4-fluoro-2-Methoxy-5-nitrobenzene
• Synonyms: 1-broMo-4-fluoro-2-Methoxy-5-nitrobenzene
• CAS NO: 935288-20-3
• Molecular Formula: C₇H₅BrFNO₃
• Molecular Weight: 250.0219032
• Mol File: 935288-20-3.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 299.7±35.0 °C(Predicted)
• Appearance: /
• Density: 1.716±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 1-broMo-4-fluoro-2-Methoxy-5-nitrobenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1-broMo-4-fluoro-2-Methoxy-5-nitrobenzene(935288-20-3)
• EPA Substance Registry System: 1-broMo-4-fluoro-2-Methoxy-5-nitrobenzene(935288-20-3)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 935288-20-3(Hazardous Substances Data)

Usage

Description

1-bromo-4-fluoro-2-methoxy-5-nitrobenzene is a chemical compound with the molecular formula C7H6BrFNO3. It is a derivative of benzene with a bromine atom, a fluorine atom, a methoxy group, and a nitro group attached to the benzene ring. This versatile compound is commonly used in organic synthesis and pharmaceutical research due to its reactivity and potential pharmaceutical applications.

Uses

Used in Organic Synthesis:
1-bromo-4-fluoro-2-methoxy-5-nitrobenzene is used as a key intermediate in the synthesis of various organic compounds. Its unique functional groups allow for a wide range of chemical reactions, making it a valuable building block for the creation of new molecules.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 1-bromo-4-fluoro-2-methoxy-5-nitrobenzene is used as a starting material for the development of new drugs. Its diverse functional groups enable the design of molecules with potential therapeutic properties, contributing to the discovery of novel pharmaceutical agents.
Used in Medicinal Chemistry:
Research has shown that 1-bromo-4-fluoro-2-methoxy-5-nitrobenzene exhibits anti-inflammatory and anti-cancer properties. As a result, it is used in medicinal chemistry to explore its potential as a therapeutic agent for the treatment of various diseases, particularly those related to inflammation and cancer.
Used as a Precursor in Synthesis:
1-bromo-4-fluoro-2-methoxy-5-nitrobenzene is also a common precursor in the synthesis of various biologically active compounds. Its presence in the molecular structure of these compounds allows for the development of new pharmaceuticals and other bioactive substances with potential applications in healthcare and other industries.

Upstream product

• 1075705-01-9 4-fluoro-2-methoxy-5-nitro-phenylamine 
• 448-19-1 4-fluoro-2-methoxy-1-nitrobenzene 
• 450-91-9 4-fluoro-2-methoxyaniline 
• 450-88-4 1-bromo-4-fluoro-2-methoxybenzene 
• 345-24-4 5-bromo-2,4-difluoronitrobenzene 
• 124-41-4 sodium methylate 

Downstream Products

• 1352244-78-0 1-(2-bromo-5-methoxy-4-nitrophenyl)-4-methylpiperazine 
• 1352244-79-1 1-(4-bromo-5-methoxy-2-nitrophenyl)-4-methylpiperazine 

Relevant articles and documents

THERAPEUTIC COMPOUNDS AND METHODS OF USE

The invention relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.

2, 4-DI-(NITROGEN CONTAINING GROUP) SUBSTITUTED PYRIMIDINE COMPOUND AND PREPARATION METHOD AND USE THEREOF

Provided are a 2, 4-di-(nitrogen containing group) substituted pyrimidine compound represented by a general formula (I), a pharmaceutically acceptable salt and a stereoisomer thereof, a preparation method thereof, and a use thereof in preparation of anti-tumor drugs. The compound having a structural feature shown in the general formula (I) can selectively suppress activity of mutant epidermal growth factor receptors (EGFR), including single-mutant EGFR (T790M) and double-mutant EGFR (including L858R/T790M and ex19del/T790M), and can suppress activity of single gain-of-function mutant EGFR (including L858R and ex19del) as well. The compound has a weak suppression effect on wild-type EFGR and a very high selectivity, and thus it has a potential to be used in preparation of drugs for treating EGFR mutant tumors, especially non-small cell lung cancer (NSCLC) comprising a T790M EGFR mutation.

2-ARYL- AND 2-ARYLALKYL-BENZIMIDAZOLES AS MIDH1 INHIBITORS

The present invention relates to 2-Aryl- and 2-Arylalkyl-benzimidazoles of general formula (I) : in which A, R1, R4, R5, R6, R7, R8, R9, R10 and R11 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.